Twin sisters living with heart failure are calling for an end to what they say is a postcode lottery when it comes to ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Beta blockers are go-to meds for many people who've survived a heart attack, but might not be needed for patients whose ...

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...